PETA has released records indicating that Pfizer used sick monkeys in drug testing, prompting the organization to urge a review of experiments conducted at the University of Louisiana’s New Iberia Research Center (NIRC). The records suggest that monkeys with pre-existing health issues were not disqualified from studies intended to inform human health. PETA is calling on Pfizer, Charles River Laboratories, and NIRC to explain these practices and raises concerns about similar occurrences in other laboratories.

Bank of Montreal (BMO) is offering US$2.151 million in autocallable barrier notes due April 20, 2029, linked to the performance of the VanEck Gold Miners ETF (GDX), NASDAQ-100 Index (NDX), and Russell 2000 Index (RTY). These notes provide a potential monthly contingent coupon of 0.91% (10.92% p.a.) with a memory coupon feature. Investors face risks including potential principal loss if a Trigger Event occurs (any reference asset falling below 50% of its initial level) and the possibility of early automatic redemption.

PNC's CEO, Bill Demchak, acknowledges that the bank's ambitious $2 billion branch expansion is progressing well but has presented unexpected challenges. The company has successfully opened 34 new branches as part of its goal to establish 300 by 2030. The article highlights that the rollout strategy is gaining momentum despite its complexities.

Voltaren's Swiss-licensed topical gel (CH-Lizenz), managed by Novartis, maintains strong demand for pain relief despite increasing healthcare costs and pricing pressures in Switzerland. The article examines how Novartis's licensing strategy impacts consumer access and stock stability, highlighting Voltaren's market position, competition, and the risks and opportunities for investors. Key factors include regulatory reviews, supply chain vulnerabilities, and potential shifts in Novartis's consumer health portfolio, all while addressing the product's relevance for a global audience, including the U.S. market.

Vertex Pharmaceuticals maintains strong revenue through its dominance in cystic fibrosis treatments like Trikafta, which addresses the genetic causes in most CF patients. The company is actively diversifying its pipeline into new areas such as non-opioid pain therapy (suzertrigine), kidney disease (inaxaplin), and gene-edited therapies for type 1 diabetes. This strategy aims to sustain long-term growth beyond its established CF market, balancing proven success with ambitious expansion into high-value, unmet medical needs.

Pfizer's COVID-19 vaccine, Comirnaty, saw a dramatic revenue drop from over $37 billion in 2022 to below $10 billion by 2025 as the pandemic subsided. This significant shift has forced Pfizer to pivot its strategy towards diversifying its portfolio, particularly through acquisitions in oncology, to sustain growth. The company is now focusing on R&D and new drug development to offset the decline in vaccine sales and manage increasing competition and investor scrutiny.

Trimble Inc. provides software, hardware, and services for construction, agriculture, and transportation, industries increasingly focused on data and technology for efficiency. The company's core business model, spanning Transportation & Logistics, Buildings & Infrastructure, and Geospatial segments, positions it to capitalize on global infrastructure spending and digital transformation trends. Trimble's strategic shift towards recurring SaaS revenue and its integrated approach give it a strong competitive edge, especially in the growing U.S. and English-speaking markets, despite potential risks from economic slowdowns and supply chain issues.

Adobe and Figma shares experienced pressure on Friday following Anthropic's launch of "Claude Design," a new AI tool focused on visual design. This development raised concerns among investors, leading to a drop in Adobe's stock. The article suggests Anthropic's new offering is seen as a potential competitor in the visual design space.

Linde plc, a global leader in industrial gases, is positioned for growth due to increasing demand from semiconductor manufacturing, clean energy initiatives, and manufacturing reshoring. The company's robust business model, featuring long-term contracts and a presence in essential industries, provides reliable cash flows and stability. While facing potential risks from economic slowdowns and energy costs, analysts largely maintain a positive outlook, citing Linde's strong free cash flow and strategic investments in sustainable technologies.

The article discusses how Applied Materials (US0382221051) is central to the AI infrastructure boom as AI shifts from software to physical hardware. It highlights the company's role in advanced chip production, its core business in semiconductor manufacturing equipment, and the tailwinds from AI demand and the CHIPS Act. The piece also covers analyst views, potential risks, and future catalysts for investors.